Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
CIP2A
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "CIP2A" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
2
2 Cited Publications
Target:
Research Areas:
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
1
1 Cited Publications
Cat. No.: HY-N4317
CAS No.: 28342-31-6
Category:
Alkaloids Quinoline Alkaloids Macleaya cordata (Willd.) R. Br. Plants Disease Research Fields Papaveraceae Extract Cancer
Target:
Cat. No.: HY-RS02718
Target:
Research Areas:
CIP2A Human Pre-designed siRNA Set A contains three designed siRNAs for CIP2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS24865
Target:
Research Areas:
Cip2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Cip2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18384
Target:
Research Areas:
Cip2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cip2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-139296
CAS No.: 1403933-79-8
PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities . PP2A Cancerous-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-P88078A
Synonyms: CIP2A; p90
Cat. No.: HY-189209
CAS No.: 850824-74-7
Target:
Research Areas:
TopBP1-IN-3 is an inhibitor of the TopBP1 BRCT7/8 domain. TopBP1-IN-3 disrupts the BRCT7/8-dependent interactions between TopBP1 and E2F1, mutp53, MIZ1, PLK1, and CIP2A, without affecting its protein binding mediated by other BRCT domains. TopBP1-IN-3 can be used for the research of ovarian cancer and breast cancer .
Cat. No.: HY-P12219
Synonyms: OP449
Research Areas:
COG449 (OP449) is a cell-penetrating peptide that binds to SET, prevents the formation of the SET-PP2A complex, and restores PP2A phosphatase activity. COG449 decreases the phosphorylation levels of AKT 308, ERK1/2, NFkB p65, and c-MYC S62, and reduces c-MYC stability and target gene expression. COG449 induces apoptosis, autophagy, and histone H3 hyperacetylation, and decreases the levels of SET, CIP2A, SETBP1, and Mcl-1. COG449 reduces cancer cell viability and decreases tumor mass in xenograft models. COG449 can be used for research on various cancers such as oral squamous cell carcinoma, T-cell acute lymphoblastic leukemia, B-CLL, non-Hodgkin lymphoma, and breast cancer [2] .
Cat. No.: HY-W320366
CAS No.: 896074-75-2
Target:
Research Areas:
TopBP1-IN-5 is a TopBP1-BRCT7/8 inhibitor (IC50=2.47-3.8 nM). TopBP1-IN-5 selectively disrupts the interaction of TopBP1-BRCT7/8 with E2F1, mutp53, MIZ1, PLK1, CIP2A, and Top2A, without affecting BRCT1/2- and BRCT5-mediated interactions. TopBP1-IN-5 activates caspase-3/7 and caspase-8 to induce prometaphase arrest, mitotic catastrophe, and apoptosis, while inhibiting the MYC transcriptional program and enhancing the binding of MIZ1 to the p21Cip1 promoter. TopBP1-IN-5 exhibits broad-spectrum anticancer activity in triple-negative breast cancer, ovarian cancer, lung cancer, and acute myeloid leukemia models, and can be used for research on related cancers .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
